Topic: checkpoint inhibitors
Right now, Roche’s Tecentriq is the only I-O drug approved in triple negative breast cancer. And it looks like it’ll stay that way for awhile.
Roche knows how things work with England’s cost watchdogs, and it put that knowledge to use to score backing for Tecentriq in lung cancer.
Gastric cancer is a tough nut to crack, and Merck superstar Keytruda has stumbled in the disease area—again.
Bristol-Myers Squibb investors have been dreading the arrival of Merck’s Keytruda in kidney cancer, one of Opdivo’s key growth areas. BMS’ execs? Not so much.
Bristol-Myers Squibb already has one Opdivo approval in previously treated head and neck cancer, but it won’t make that two.
BMS investors knew trouble would come for Opdivo when Merck’s Keytruda entered the kidney cancer arena, but that trouble arrived two months early.
Roche’s Tecentriq scored some big wins lately, including a pair of first-in-class approvals. But in other cancers, it's decided to pull the plug.
Opdivo, the Bristol-Myers cancer drug co-developed with Japan’s Ono, is a global cash cow—but a Nobel winner behind the drug isn't happy with his cut.
After a blow in first-line lung cancer, BMS is clinging to its share of the second-line market. And it’s hoping new long-term data can help it hang on.
Last AACR, Merck’s Keytruda-chemo put up stellar lung cancer data. This year, Merck was back to show the combo held up in tough-to-treat patients.